Company news
Cel-sci Corporation (AMEX:CVM) news
Cel-sci Corporation news releases on 6ix. Latest, Aug 17, 2026: CEL-SCI Reports Fiscal Third Quarter 2026 Results
Press releases & updates
CEL-SCI Reports Fiscal Third Quarter 2026 Results
August 17, 2026
Cel-Sci: Fiscal Q3 Earnings Snapshot
August 14, 2026
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
July 13, 2026
CEL-SCI Announces Closing of Offering
June 16, 2026
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
June 16, 2026
CEL-SCI Corporation Announces Pricing of Offering
June 14, 2026
CEL-SCI Reports Fiscal Second Quarter 2026 Results
May 18, 2026
Cel-Sci: Fiscal Q2 Earnings Snapshot
May 15, 2026
CEL-SCI Corporation Announces Pricing of Public Offering
May 11, 2026
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
May 11, 2026
CEL-SCI Reports Fiscal First Quarter 2026 Results
February 18, 2026
Cel-Sci: Fiscal Q1 Earnings Snapshot
February 17, 2026
CEL-SCI Reports Fiscal 2025 Results
December 29, 2025
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
October 20, 2025
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
October 10, 2025
CEL-SCI Announces Closing of $10 Million Public Offering
August 29, 2025
CEL-SCI Announces Pricing of $10 Million Public Offering
August 27, 2025
CEL-SCI Announces Proposed Public Offering
August 27, 2025
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
August 14, 2025
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
August 13, 2025
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
July 14, 2025
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
July 11, 2025
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
July 11, 2025
CEL-SCI Announces Closing of Public Offering
May 23, 2025
CEL-SCI Announces Pricing of Public Offering
May 21, 2025
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
May 21, 2025
CEL-SCI Announces Combination of Common Stock
May 19, 2025
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
May 15, 2025
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
April 23, 2025